• Moderna Inc. is trading 4.6% up today at $64.67, extending a powerful multi-day rally driven by recent company-specific developments.
  • The FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) is meeting today, June 18, 2026, to discuss Moderna's seasonal flu vaccine (mFlusiva).
  • Positive FDA briefing documents released prior to the meeting and Moderna's recent organizational changes aimed at future product launches have fueled investor optimism.
  • The stock has climbed significantly from $47.73 on June 9, bolstered by sharp gains of 11.6% on June 17 and 6.3% on June 16.